Dad Taimur, Sarnak Mark J
Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
Semin Dial. 2016 Sep;29(5):366-73. doi: 10.1111/sdi.12517. Epub 2016 May 26.
Pericarditis and pericardial effusions are not uncommon in patients with end-stage renal disease (ESRD). Etiologies include those found in the general population along with two entities unique to patients with kidney disease, namely uremic and dialysis-associated pericarditis. Uremic pericarditis has been arbitrarily defined as pericarditis that develops before or within 8 weeks of initiation of dialysis, while dialysis-associated pericarditis is used to define pericarditis in patients on dialysis for more than 8 weeks. Retention of uremic toxins is likely a major contributor to uremic and dialysis-associated pericarditis although their exact cause is not known. Indeed, whether they are actually distinct entities is uncertain. Symptoms and signs of pericarditis differ in patients with ESRD compared to the non-ESRD population. Management has not been well studied and ranges from initiation and intensification of dialysis to percutaneous or open drainage for large effusions. This review covers the literature on this topic but emphasizes that most of the data are old and of relatively poor quality, and therefore additional research is needed.
心包炎和心包积液在终末期肾病(ESRD)患者中并不少见。病因包括一般人群中发现的病因以及肾病患者特有的两种情况,即尿毒症性心包炎和透析相关性心包炎。尿毒症性心包炎被随意定义为在开始透析前或开始透析后8周内发生的心包炎,而透析相关性心包炎用于定义透析超过8周的患者的心包炎。尽管尿毒症毒素的确切病因尚不清楚,但尿毒症毒素的潴留可能是尿毒症性和透析相关性心包炎的主要原因。事实上,它们是否实际上是不同的实体尚不确定。与非ESRD人群相比,ESRD患者心包炎的症状和体征有所不同。对于心包炎的管理研究不足,治疗范围从开始和加强透析到对大量积液进行经皮或开放引流。本综述涵盖了关于该主题的文献,但强调大多数数据较陈旧且质量相对较差,因此需要更多的研究。